bioRxivCell BiologyPreprint
Application of a High-Biomimetic Tumor Organoid-CAF Co-Culture Model for the Efficacy Evaluation of CAR-T Drugs
Jiagen LiiD, Jian WangiD, Yan SuniD, Jianchuang Liu, Lijie RongiD, Rongrong Xiao, Xiaoni AiiD
Abstract
The tumor microenvironment (TME) is a complex ecosystem composed of tumor cells, cancer-associated fibroblasts (CAFs), immune suppressive cells, and the extracellular matrix (ECM), playing a crucial role in tumor development and CAR-T cell therapy efficacy. CAR-T therapy has shown promise in hematological malignancies but faces challenges in solid tumors due to the TMEs ability to suppress CAR-T cell infiltration, proliferation, and cytotoxicity. Traditional drug evaluation models, such as 2D cell cultures and animal models, have significant limitations due to oversimplification of the in vivo environment or physiological differences between species. Organoid models offer a more biomimetic approach but often fail to fully recapitulate the TMEs complexity and heterogeneity. Our research developed a tumor organoid and CAF co-culture model using the IBAC co-culture chip, demonstrating that CAFs significantly impact CAR-T cell therapy efficacy by forming physical (e.g., fibronectin) and chemical (e.g., IL-10) barriers that prevent CAR-T cell infiltration and cytotoxicity. This model provides a high-biomimetic platform for investigating the TMEs effects on CAR-T therapy and highlights the importance of incorporating a comprehensive stromal component into in vitro models to enhance their predictive power for cancer treatment.
- assay: organoid / primary culture
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A colorectal cancer organoid-CAF co-culture chip for drug screening and personalized therapy
Rongrong Xiao, Zhijie Wang, … Xiaoni Ai·bioRxiv·Jun 19, 2026
- A Hybrid Multiscale Model for Predicting CAR-T Therapy Outcomes in SolidTumors
Mohammad R. Nikmaneshi, Lance L. Munn·Scientific ReportsPeer-reviewed·May 23, 2026
- Assessment of CAR-T mediated and targeted cytotoxicity in 3D microfluidic TBNC co-culture models for combination therapy
K. A. F. Paterson, S. Paterson, … M. Zagnoni·bioRxiv·Sep 14, 2021
- A scalable tumor-vasculature-on-chip for CAR T cell trafficking and efficacy studies
Luuk de Haan, Aleksandra Olczyk, … Karla C. S. Queiroz·bioRxiv·Feb 9, 2026
- CAR-T-drug conjugate against solid tumor
Shan Xin, Yanzhi Feng, … Sidi Chen·bioRxiv·Jan 2, 2026
- CAR T cell infiltration and cytotoxic killing within the core of 3D breast cancer spheroids under control of antigen sensing in microwell arrays
Y. Cho, M. Laird, … I. K. Zervantonakis·bioRxiv·Mar 14, 2024